Dainippon Sumitomo Halts Dementia Drug Development
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Dainippon Sumitomo Pharmaceutical halted April 17 the development for dementia agent AC-3933 in Japan and abroad. The drug is currently in Phase II trials in Japan, the U.S. and Europe. The company cited that the U.S. Phase II trial results did not meet the criteria it had envisioned. (Click here for more - Japanese language